Clinical trial
G207 Followed by Radiation Therapy in Malignant Glioma
NCT00157703 · MediGene, Industry · Completed
Key facts
| NCT number | NCT00157703 |
|---|---|
| Title | G207 Followed by Radiation Therapy in Malignant Glioma |
| Official title | A Staged Phase 1 Study of the Treatment of Malignant Glioma With G207, a Genetically Engineered HSV-1, Followed by Radiation Therapy |
| Lead sponsor | MediGene, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malignant Glioma |
| Intervention type | Drug |
| Interventions | G207 |
| Enrollment | 9 |
| Start date | May 1, 2005 |
| Primary completion | Oct 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Sep 12, 2005 |
| Last update posted | Dec 16, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: